Orbai Ana-Maria, Mease Philip J, de Wit Maarten, Kalyoncu Umut, Campbell Willemina, Tillett William, Eder Lihi, Elmamoun Musaab, FitzGerald Oliver, Gladman Dafna D, Goel Niti, Gossec Laure, Lindsay Chris A, Steinkoenig Ingrid, Helliwell Philip S, McHugh Neil J, Strand Vibeke, Ogdie Alexis
From the Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington, USA; VU Medical Centre, Amsterdam, The Netherlands, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA; Department of Internal Medicine, Division of Rheumatology, Hacettepe University Ankara, Ankara, Turkey; Toronto Western Hospital, Toronto, Ontario, Canada; Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Rheumatology, St. Vincent's University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; University of Toronto, Krembil Research Institute, Psoriatic Arthritis Program, University Health Network, Toronto, Ontario, Canada; Quintiles, Duke University School of Medicine, Durham, North Carolina, USA; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Cleveland Clinic, Cleveland, Ohio, USA; University of Leeds, Leeds, UK, and Bradford Hospitals National Health Service (NHS) Foundation Trust, Bradford, UK; Division of Immunology, Stanford University, Palo Alto, California, USA; University of Pennsylvania, Philadelphia, Pennsylvania, USA.A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; U. Kalyoncu, MD, Division of Rheumatology, Johns Hopkins University and Department of Internal Medicine, Division of Rheumatology, Hacettepe University Ankara; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; W. Tillett, BSc, MB, ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; L. Eder, MD, PhD, Toronto We
J Rheumatol. 2016 May;43(5):965-9. doi: 10.3899/jrheum.160116.
The GRAPPA-OMERACT psoriatic arthritis (PsA) working group is in the process of updating the PsA core domain set to improve and standardize the measurement of PsA outcomes. Work streams comprise literature reviews of domains and outcome measurement instruments, an international qualitative research project with PsA patients to generate domains important to patients, outcome measurement instrument assessment, conduct of domain consensus panels with patients and physicians, and evidence-based selection of instruments. Patient research partners are involved in each of the projects. The working group will present findings and seek endorsement for the new PsA core domain set, outcome measurement set, and research agenda at the OMERACT meeting in May 2016.
GRAPPA-OMERACT银屑病关节炎（PsA）工作组正在更新PsA核心领域集，以改进和规范PsA结局的测量。工作流程包括对领域和结局测量工具的文献综述、一项针对PsA患者的国际定性研究项目以生成对患者重要的领域、结局测量工具评估、与患者和医生进行领域共识小组讨论以及基于证据的工具选择。患者研究伙伴参与了每个项目。该工作组将在2016年5月的OMERACT会议上展示研究结果，并寻求对新的PsA核心领域集、结局测量集和研究议程的认可。
